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 BACKGROUND 
 Chronic diarrhea is a common problem in patients with 
acquired immunodeficiency syndrome (AIDS) in Haiti and 
other resource-limited settings. 1– 5 Observational studies sug-
gest that chronic diarrhea is associated with increased mortal-
ity in patients with AIDS, even after initiation of antiretroviral 
therapy (ART). 6, 7 Some have reported poor absorption of anti-
microbial medications in patients with diarrhea and suggested 
that the increased mortality in patients with AIDS diarrhea 
may be related to malabsorption of antiretroviral drugs. 8– 13 
Low plasma concentrations of some antiretroviral drugs pre-
dict treatment failure. 14– 17 
 Therefore, we performed a prospective study to evalu-
ate whether human immunodeficiency virus (HIV)-infected 
patients with chronic diarrhea at the time of ART initiation 
have lower plasma antiretroviral drug concentrations and 
higher rates of virologic failure compared with patients with-
out chronic diarrhea. 
 METHODS 
 Study setting.  The study was conducted at the Groupe 
Haitien d’Etude du Sarcome de Kaposi et des Infections 
Opportunistes (GHESKIO) Center in Port-au-Prince, Haiti. 
Patients with AIDS at GHESKIO receive treatment accord-
ing to guidelines published by the World Health Organization 
(WHO), 18 and protocols and outcomes have been described 
previously. 19, 20 
 Study design.  This was a matched-pair cohort study. We 
recruited HIV-1-infected patients who were initiating ART 
at GHESKIO who reported 3 weeks of diarrhea and con-
trols also initiating therapy matched for age, sex, and CD4 
count. All participants were initiated on antiretroviral medica-
tions and followed for 24 weeks. Plasma drug concentrations 
were measured at 2 and 4 weeks. Plasma HIV-1 RNA levels 
were measured at baseline, 2 weeks, 4 weeks, and at 24 weeks. 
We compared drug concentrations and HIV-1 RNA levels 
between patients with diarrhea and controls. 
 Study population.  Entry criteria included: HIV-1 infected; 
age ≥ 18 years; satisfy WHO criteria for initiating ART; a 
hemoglobin > 7.5 mg/dL; creatinine ≤ 1.5 × upper limit of nor-
mal (ULN), aspartate (AST) aminotransferase (previously 
SGOT), alanine aminotransferase (ALT) (previously SGPT) 
≤ 3 × ULN, and total bilirubin ≤ 2.5 × ULN. 
 Exclusion criteria included: prior antiretroviral exposure 
and requirement for medications known or predicted to inter-
act with antiretrovirals. 
 GHESKIO clinicians asked patients initiating ART about 
the presence or absence of diarrhea. A patient was offered 
enrollment as a case (diarrhea) if he/she reported at least 3 
weeks of loose stools > 3× per day. Once a case (diarrhea) 
patient was recruited, the research team worked with the 
clinicians in the ART clinic to identify and recruit a control 
matched on age within 5 years of the case; CD4 count in the 
same range (< 50; 51–100; 101–200; > 200); and sex. 
 All participants initiated therapy with efavirenz (EFV, 
600 mg every 24 hours in the evening) plus fixed-dose 
zidovudine/lamivudine (ZDV/3TC, 300/100 mg every 12 hours). 
Directly observed therapy was used to assure adherence for 
the first 4 weeks of therapy. Study personnel visited the par-
ticipants’ homes each morning to observe the ingestion of 
the morning dose. A family member or friend, designated by 
the participant, observed and documented the evening doses. 
All observed doses were recorded in a pictorial medication 
diary. 
 All participants were followed by study personnel for 24 
weeks after the initiation of therapy with study visits at 2, 4, 
and 24 weeks. 
 Laboratory assays.  Screening tests for kidney and liver 
function were performed: AST (SGOT), ALT (SGPT), and 
creatinine (VITROS; Ortho Clinical Diagnostics, Raritan, 
NJ). A complete blood count was done at baseline and at 
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each study visit (Cell-Dyn; Abbott Laboratories, Abbott Park, 
IL). A CD4 T cell count was measured at baseline and at 24 
weeks (Becton, Dickinson, Franklin Lakes, NJ). The plasma 
HIV-1 RNA level was performed at baseline, 2 weeks, 4 
weeks, and 24 weeks (NASBA Easy Q; bioMérieux, Lyons, 
France). 
 The d-xylose carbohydrate absorption test was performed 
at baseline and at 2 and 24 weeks. Participants fasted for 
8 hours before coming to the clinic. To perform the test, 
study personnel provided each participant with 25 grams 
of d-Xylose (Xylo PFAN, Savage Laboratories, Melville, 
NY ) dissolved in 250 mL of water. The participant was then 
asked to drink an additional 250 mL of water. Urine was col-
lected in a large plastic container over the next 5 hours. A 
25 mL aliquot was preserved in sodium fluoride (NaF), and 
the total volume of the sample was recorded. 
 A stool sample was collected at enrollment for each patient. 
Routine examinations performed by trained technologists at 
GHESKIO included: guaiac testing, methylene blue stain-
ing on a wet mount for white blood cells, and a microscopic 
exam for ova and parasites. Coccidial oocysts were identified 
with modified Kinyoun acid-fast staining. Aliquots of unpre-
served stool were frozen for batch testing by polymerase 
chain reaction for  Cryptosporidium sp., enteroaggregative 
 Escherichia coli ,  Campylobacter jejeuni ,  Clostridium difficile , 
and  Entero cytozoon bineusi . 21– 26 Quantitative lactoferrin 
enzyme-linked immunosorbent assay (IBD-Scan; Techlabs, 
Blacksburg, VA) was also performed on frozen stool samples. 
Antimicrobial susceptibility testing was performed by disk 
diffusion. 
 Blood plasma samples were obtained from patients when 
they came to the GHESKIO clinic for their morning dose of 
ART on the day of the 2-week and 4-week study visits. Plasma 
samples for drug assays were obtained before the morning dose 
of ZDV/3TC. Time since the last doses of efavirenz, ZDV, and 
3TC were documented. Plasma was separated by centrifuga-
tion at 4°C and stored at −70°C. Efavirenz, ZDV, and 3TC were 
quantified using two validated methods in the UNC Center 
for AIDS Research Clinical Pharmacology and Analytical 
Chemistry Core. 27, 28 The dynamic range for efavirenz was 25 to 
10,000 ng/mL, intra- and interday precision of 4.8–5.5%, and 
accuracy of 100.4–101.7%. The dynamic range for ZDV and 
3TC was 10–10,000 ng/mL, with intra- and interday precision 
of < 7%, and accuracy of ≥ 90% for all concentrations. Samples 
below level of quantitation (BLQ) were considered to be 50% 
of the lowest level detectable of the assay. Samples below level 
of detection (BLD) were considered to be “0.” 
 Statistical analysis.  Data were analyzed using SPSS version 
17.0 (Chicago, IL). The primary analysis was to compare anti-
retroviral drug concentrations and plasma HIV-1 RNA levels 
between patients with diarrhea and controls. For each partic-
ipant a single plasma drug concentration value derived and 
based on the geometric mean of Week 2 and Week 4 values 
for zidovudine, lamivudine, and efavirenz was used for statis-
tical analyses. In one individual without Week 2 data and one 
individual without Week 4 data, the Week 4 and Week 2 val-
ues were used to represent geometric mean, respectively. The 
geometric mean concentrations for each drug were then used 
to determine medians, interquartile ranges (IQRs), and cor-
relations among groups. The median values were compared 
between groups using Wilcoxon rank sum test for paired vari-
ables and Mann-Whitney test for unpaired variables. 
 The HIV-1 RNA levels at baseline and Week 2 were log 10 
transformed, and we reported the decrease from baseline at 
2 weeks. The median values and IQRs were reported for each 
group, and medians were compared between groups using the 
Wilcoxon rank sum test. At Week 24, we reported the percent 
of participants with plasma HIV-1 RNA level < 50 copies/mm 3 
and compared groups using the χ 2 squared test. To correct for 
multiplicity of primary endpoints, we set the significance level 
at a  P value of 0.01. 
 Baseline characteristics and clinical outcomes between 
index and control participants were compared using a χ 2 test 
for categorical variables and the Mann-Whitney test for con-
tinuous variables. Significance was pre-assigned as  P < 0.05. 
 Ethical review.  Ethical review boards at GHESKIO, Weill 
Cornell Medical College, and the University of Virginia 
approved the study. 
 RESULTS 
 Baseline characteristics of study participants at initiation of 
antiretroviral therapy.  Twenty-six HIV-1 infected patients with 
active diarrhea were enrolled. A matched control was enrolled 
for each case. Of note, one matched-control patient died 9 days 
after enrollment because of a cerebral infection. An additional 
control was subsequently recruited as a replacement. The data 
from the deceased patient is not included in this analysis. 
 The baseline clinical and demographic characteristics of 
the 26 patients with and 26 without chronic diarrhea are pre-
sented in  Table 1 . The low median CD4 count and high HIV 
RNA level show advanced HIV disease and immune compro-
mise in all patients. Women with diarrhea had significantly 
lower body mass index and hemoglobin levels compared with 
women without diarrhea. The patients with diarrhea had a sig-
nificantly higher mean quantitative lactoferrin in their stool 
samples compared with those without diarrhea (37.83 μg/mL 
versus 14.71 μg/mL;  P = 0.001). Lactoferrin is a marker of 
gastrointestinal inflammation. There was a trend toward 
lower urine d-xylose excretion in patients with diarrhea 
compared with those without diarrhea. The d-xylose excre-
tion is a measure of gastrointestinal carbohydrate absorptive 
capacity. 
 At enrollment, 47/52 (88%) participants provided a stool 
sample. Stool analysis revealed that the case and control 
populations had similar rates of enteric pathogen identifica-
tion ( Table 1 ). Enteroaggregative  E. coli (EAEC) was the 
most commonly identified pathogen (29/46; 63%). 5/6 (83%) 
of EAEC isolates tested were resistant to trimethoprim-
sulfamethoxazole. 
 All patients in the study were initiated on 3-drug ART. For 
the patients with chronic diarrhea, the median duration of 
diarrhea following initiation of antiretroviral therapy was 19 
days (IQR 14–27 days). 
 Plasma antiretroviral drug levels and HIV-1 RNA levels. 
 Plasma samples for drug concentrations of both ZDV/3TC 
and efavirenz were obtained 14 (IQR 13–15) hours and 13 
(IQR 13–14) hours after the previous doses at 2 and 4 weeks, 
respectively. Mean plasma antiretroviral drug concentrations 
did not differ between patients with diarrhea and controls at 
Week 2 or Week 4; nor did the geometric mean values for each 
antiretroviral drug differ,  Table 2 . The geometric mean zido-
vudine concentration was actually higher for patients with 
diarrhea (121.86 ng/mL versus 32.36 ng/mL,  P = 0.18). There 
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was no association between plasma drug concentrations and 
particular enteric pathogens, quantitative lactoferrin levels, or 
d-xylose excretion. 
 There was no important difference in plasma HIV-1 RNA 
levels between cases with diarrhea and controls at Week 2, 
Week 4, or Week 24. At Weeks 2 and 4, the patients with diar-
rhea tended to have a greater reduction in viral load than 
controls. At 2 weeks, the patients with diarrhea had a median 
log-transformed reduction in viral load of 5.39; patients with-
out diarrhea had a log-transformed reduction of 5.14 ( P = 0.07). 
At 4 weeks, a similar pattern in viral load reduction remained 
(5.40 versus 5.17;  P = 0.07). At Week 24, 18/25 (72%) patients 
with diarrhea and 16/24 (68%) patients without diarrhea had 
achieved an undetectable viral load ( P = 0.69). 
 Of note, the patients who achieved an undetectable viral 
load at Week 24, regardless of the presence or absence of diar-
rhea at baseline, had higher plasma drug concentrations for 
all three antiretrovirals at Weeks 2 and 4 and by geometric 
mean. The difference in EFV levels was significant ( Table 3 
and  Figure 1 ). 
 Other measures of treatment response.  At 24 weeks, both 
groups had good immunologic responses. Patients with diar-
rhea had a median increase of 119 cells/mm 3 (IQR: 50–174 
cells/mm 3 ), and patients without diarrhea had a median 
increase of 120 cells/mm 3 (IQR: 77–158 cells/mm 3 ). 
 Patients with diarrhea tended to gain more weight than 
patients without diarrhea. At Week 4, the patients with diar-
rhea had significantly greater weight gain compared with 
those without diarrhea (3% versus 1% of total body weight; 
P = 0.02). By 24 weeks, the group with diarrhea had still 
gained more weight (13.5% versus 9.0% of total body weight; 
P = 0.243). By 24 weeks, the urine d-xylose excretion had 
normalized in both groups with a mean of 30.7% in the patients 
with diarrhea and a mean of 31.7% in the controls. 
 DISCUSSION 
 This study demonstrates that AIDS diarrhea at the initia-
tion of ART does not significantly affect drug concentrations 
of AZT, 3TC, or EFV in this profoundly immune-suppressed 
population with adequate renal and hepatic function. After 
initiation of ART, plasma HIV-1 RNA levels and other mea-
sures of treatment response were similar between patients 
with AIDS diarrhea and matched controls. 
 Our study prospectively examined plasma antiretroviral 
drug concentrations, plasma HIV1-RNA levels, and clinical 
outcomes relative to the presence or absence of chronic diar-
rhea. The clinical response to ART by patients with diarrhea 
was at least as robust as matched controls without diarrhea. In 
fact, patients with diarrhea had a trend toward greater reduc-
tion in viral load measured at Week 2 and Week 4 than those 
without diarrhea. They had an equally good rise in CD4 count, 
achievement of undetectable HIV viral load at 24 weeks, and 
gain of weight. 
 Table 1 
 Baseline characteristics of index and control patients * 
 Variable
Patients with chronic 
diarrhea ( N = 26)
Patients without chronic 
diarrhea ( N = 26)  P value
Matched characteristics 
for each pair
Age(years) (median [IQR]) 38 [32–44] 37 [34–44] 0.832
% female 54 54 1.000
Baseline CD4 count (cells/mm 3 ) (median [IQR]) 59 [21–148] 64 [24–151] 0.967
Baseline viral load (copies/mm 3 ) (median [IQR]) 250,000 [125,000–845,000] 145,000 [57,000–277,000] 0.339
% living on < $1/day 55 54 0.827
% living with partner 50 42 0.578
% Completing primary education or above 62 50 0.602
% who were on TMP-SMX prophylaxis 96 92 1.000
BMI (kg/m 2 ): females (kg/m 2 ) (median [IQR]) 20.3 [17.2–21.5] 23.1 [21.3–25.1] 0.004
BMI(kg/m 2 ): males (median [IQR]) 20.2 [17.5–24.8] 20.5 [19.1–23.6] 0.934
Hemoglobin (gm/dL): females (median [IQR]) 9.4 [8.7–10.4] 10.6 [9.9–11.4] 0.014
Hemoglobin (gm/dL): males (median [IQR]) 10.5 [9.3–12.9] 11.7 [10.3–12.6] 0.492
D-xylose excretion (%; normal > 16%): (median [IQR]) 14.3 [5.4–24.6] 18.4 [13.4–29.2] 0.275




 Cryptosporidium sp. 7/23 (30%) 10/23 (44%) 0.359
Enteroaggregative  E. coli 16/23 (70%) 13/23 (57%) 0.359
 E. bieneusi 3/23 (13%) 4/23 (17%) 0.681
 C. jejeuni 3/23 (13%) 2/23 (9%) 0.636
 C. difficile 2/23 (9%) 1/23 (4%) 0.550
2 or more pathogens 10/23 (44%) 10/23 (44%) 1.000
No pathogens 4/23 (17%) 5/23 (22%) 0.710
 *  IQR = interquartile range; TMP-SMX = trimethoprim-sulfamethoxazole; BMI = body mass index; PCR = polymerase chain reaction. 
 Table 2 
 Antiretroviral drug concentrations and HIV-1 RNA levels in patients with and without diarrhea * 
Measure Patients with chronic diarrhea ( N = 26) Patients without chronic diarrhea ( N = 26)  P value
Plasma zidovudine concentration (ng/mL) [IQR] 23.04 [BLD–74.36] BLD [BLD–35.83] 0.07
Plasma lamivudine concentration (ng/mL) [IQR] 114.12 [79.54–175.51] 146.90 [78.72–194.57] 0.38
Efavirenz concentration (ng/mL) [IQR] 3066.32 [2361.55–6533.37] 3294.32 [1734.40–7069.68] 0.87
2-week change in log 10 HIV-1 RNA level [IQR] 5.39 [5.09–5.93] 5.14 [4.7–5.43] 0.07
Proportion of participants with plasma HIV-1 
RNA < 50 copies/mm 3 at 24 weeks 18/25 (72%) 16/24 (68%) 0.69
 *  BLD = below level of detection; IQR = interquarile range; HIV-1 = human immunodeficiency virus-1. 
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 A previous study showing a correlation between AIDS 
diarrhea and low antiretroviral drug concentrations exam-
ined patients who presented with diarrhea after initiation of 
ART. 10 In this case, the occurrence of diarrhea during ART 
may have been an effect of poor adherence and treatment fail-
ure, rather than the cause. Other studies suggesting that AIDS 
diarrhea is in itself related to poor treatment outcome may 
not have controlled for HIV disease stage and severe immune 
suppression. As demonstrated in our study, chronic diarrhea 
is a clinical marker for advanced HIV disease; the median 
CD4 count of our patients with AIDS diarrhea was only 
59 cells/mm 3 . 6 
 Virologic outcome in our HIV-1 infected patients in Haiti 
correlated with plasma efavirenz concentrations early in ther-
apy. Of note, patients in the current study received directly 
observed therapy and therefore differences in adherence 
do not explain the variation in efavirenz exposure. Rather, 
it appears that an individual’s efavirenz exposure effects 
response to ART. The current study shows that low efavirenz 
exposures are not caused by diarrhea. Our previous analy-
sis suggests that low efavirenz concentrations in patients in 
Haiti may be related to genetic polymorphisms in the cyto-
chrome P450 (CYP) 2B6 and thus differences in metabolic 
rate. 29 
 Enteroaggregative  E. coli was common in our HIV-infected 
patients, which is consistent with previous reports. 26, 30, 31 As 
documented in our patients, EAEC is frequently resistant to 
widely available antimicrobials. 32, 33 Its high prevalence and 
reports that infection may negatively impact nutrition suggest 
that this pathogen and strategies for its management deserve 
further investigation. 34, 35 
 In conclusion, patients with AIDS diarrhea have advanced 
immune suppression. However, they respond well to ART 
with no significant differences in drug exposure for ZDV, 3TC, 
and EFV. On the basis of these findings, we do not recommend 
delay in ART until cessation of diarrhea or a dosage adjust-
ment of ZDV, 3TC, and EFV for patients with AIDS diarrhea. 
Rather, we encourage prompt initiation of ART at standard 
dosing for patients with AIDS diarrhea. 
 Received September 27, 2010. Accepted for publication March 22, 
2011. 
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